Clinical trial NCT00272012: OPAL - Insulin Glulisine, Diabetes Mellitus
Official title: Efficacy and Safety of Insulin Glulisine Given as a Single Injection at Breakfast + Insulin Glargine+OAD (Oral Antidiabetic Drug) vs Insulin Glulisine Given as a Single Injection at Main Meal+Insulin Glargine+OAD in Type 2 Diabetic Patients for Which Glycemic Control is Suboptimal Using Insulin Glargine+ OAD Alone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus Type 2
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-01-04
Enrollment: 396
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective:

The primary study objective is to compare efficacy of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of change in HbA1c, from baseline to endpoint for the individual patient. The aim of the study is to demonstrate two-sided equivalence between the two therapy regimens receiving two different injection timing of Insulin glulisine.

Secondary objective:

Secondary study objectives are to compare efficacy and safety of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of:

* Change of fasting-, pre-/2h-postprandial-, mean daily and nocturnal blood glucose (baseline to endpoint)
* Change of fasting plasma glucose (baseline to endpoint)
* Response rate: Responders will be those patients with HbA1c smaller than 7.0% at study endpoint
* Insulin dose (rapid-acting, basal and total daily doses)
* Weight, body-mass index
* Hypoglycemic events
* Adverse events


Eligibility criteria: Inclusion criteria:

* Type 2 Diabetes mellitus, previously treated with combination therapy of insulin glargine + OAD (maximal tolerated dose / approved in combination with insulin according to local SPCs (Summary of Product Characteristics), not including use of a-glucosidase inhibitors) for at least 3 months
* Pre-screening HbA1c value greater/equal 7% - smaller/equal 9%
* FBG (Fasting Blood Glucose) smaller/equal 120 mg/dl (6.6 mmol/l)
* Women are either not of childbearing potential (surgically sterile, or postmenopausal for more than 2 years) or are not pregnant and agree to use a reliable contraceptive measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide.
* Ability and willingness to perform blood glucose monitoring using the sponsor-provided blood glucose meter and subject diary at home

Exclusion criteria:

* More than two FBG greater 120 mg/dl (6.6 mmol/l) as measured on 5 consecutive days before visit II
* Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation)
* Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
* Known impaired hepatic and renal function
* History of drug or alcohol abuse
* History of hypersensitivity to insulin or insulin analogues or any of the excipients in the Insulin glulisine formulation
* Treatment with any investigational drug in the last month before visit I
* Pregnant or breast-feeding women, or women planning to become pregnant during the study
* Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
* Night shift workers if they are unable to comply with the treatment regimen

Primary outcomes:
measure: Change in HbA1c.
timeFrame: from baseline to study endpoint.
Secondary outcomes:
measure: Change of pre-, 2 h postprandial and nocturnal blood glucose values
timeFrame: 8-point profile
measure: Fasting blood glucose
timeFrame: 8-point blood glucose profile values
measure: Responder rate HbA1c smaller 7 %
timeFrame: at study endpoint
measure: Insulin dose
timeFrame: rapid-acting, basal and total daily doses
measure: Weight, BMI
timeFrame: study follow-up
measure: Hypoglycemic events
timeFrame: study follow-up
measure: Adverse events.
timeFrame: study follow-up
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Sanofi-Aventis
Study officials:
affiliation: Sanofi
name: Wolfgang Landgraf, Dr.
role: STUDY_DIRECTOR
References: